DARE Q3'26 Earnings: revenue estimate is 1.57M USD

Dare Bioscience (DARE) is scheduled to release Q3'26 earnings on November 05. Analysts expect revenue of 1.57M USD and EPS of (0.16) USD. The announcement is expected at 7:00 AM ET (12:00 PM UTC).

Original reporting
Published Oct 29, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DARE Q3'26 Earnings: revenue estimate is 1.57M USD — source image
Decision brief

The 30-second read

$DARENeutralMed
01

Why it matters

The earnings preview provides the first quantitative guidance for Q3'26, offering a baseline for traders to gauge surprise.

02

Market read

Limited to DARE; broader market impact minimal.

03

What to watch

Potential upcoming clinical trial data or partnership announcements not mentioned could swing sentiment.

Relevance 6/10Novelty 6/10Timing: pre‑market on Nov 5

Background

Dare Bioscience is a micro‑cap biotech listed on Nasdaq, primarily focused on gene‑editing technologies.

Company-level read

Ticker impact

$DARENeutralMedium confidence
Context

Dare Bioscience announced its Q3'26 earnings release with revenue estimate of $1.57M and EPS of -$0.16, the first public disclosure of these figures.

Expected impact

potential volatility around the Nov 5 earnings release, likely pressure if results miss the modest estimate

Evidence & confidence

The company is small and the forecast is low‑scale; traders may react to any deviation from the $1.57M revenue guide.

Market effects

Biotech sector may see slight attention but impact limited to DARE.

U.S. small‑cap market may experience minor volume around the release.

Low

Counterpoint

Given the tiny revenue forecast, a short position could profit if the market overreacts to the release.

Key entities

  • Dare Bioscience, Inc.

    US‑listed biotech (ticker DARE) reporting Q3'26 earnings.

Related articles

$DAREMed

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.